Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.

Targeted oncology - 1 Sept 2013

Janku Filip, Wheler Jennifer J, Hong David S, Kurzrock Razelle

Abstract excerpt

Despite development of new therapies, metastatic colorectal cancer (mCRC) largely remains an incurable disease. Approximately 2-6% of colorectal cancers harbor NRAS mutations. The anti-VEGF antibody bevacizumab is a backbone of most therapeutic regimens; however, biomarkers predicting its activity are not known. We report two cases of mCRC with a Q61K NRAS mutation that had a favorable response to bevacizumab and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Biomarkers, Tumor

Share to Colorectal Neoplasms

Share to GTP Phosphohydrolases

Share to Membrane Proteins

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 23400451
DOI: 10.1007/s11523-013-0266-9
PMCID: PMC3766504

Genes

NRAS
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation.PMID 23400451Read ↗

Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.Semantic proximity Read ↗

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.Semantic proximity Read ↗

EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.Semantic proximity Read ↗

G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.Semantic proximity Read ↗

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.Semantic proximity Read ↗

Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

NRASQ61R immunohistochemistry detects both NRASQ61R and KRASQ61R mutations in colorectal cancer.Semantic proximity Read ↗

Development of BRAF V600E Mutation in NRAS Q61L Mutated Rectal Cancer.Semantic proximity Read ↗

Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.Semantic proximity Read ↗

Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors.Semantic proximity Read ↗

NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRAS Q61R or KRAS Q61R Mutation in Colorectal CarcinomaSemantic proximity Read ↗

Nonsynonymous mutations in VEGF receptor binding domain alter the efficacy of bevacizumab treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.